Cabozantinib (CBZ) is a small molecule tyrosine kinase receptor inhibitor (TKI), which targets c-Met and vascular endothelial growth factor receptor 2 (VEGFR2), that has been approved by the FDA to treat advanced renal cell carcinoma and medullary thyroid cancer (Kurzrock et al., 2011; Yakes et al., 2011). The gene discussed is KDR; the disease is renal cell carcinoma.